-
Coeptis Therapeutic Holdings Details $835M Transaction Structure with Z-Squared; Vanderbilt Report Publishes Coverage
-
Coeptis extinguishes convertible note debt with YA II PN
-
Coeptis Therapeutics (COEP): Monarch Therapeutics and SNAP Biosciences Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology
-
Nuburu (BURU) Files $100M SEC Registration Statement
-
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Coeptis Therapeutics Holdings, Inc. Merger
-
Coeptis Therapeutics (COEP) and Z Squared Inc. Announce Merger Agreement
-
Coeptis (COEP) partners with NexGenAI and Ishvara to launch tech hub in India
-
Nuburu (BURU) Announces Strategic Corporate Update Focused on Defense & Security, Advanced Technologies, and Growth Initiatives
-
Coeptis Therapeutics (COEP) files for 3.92M Share Offering by Selling Stockholders
-
Coeptis Therapeutics (COEP) Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR Cell Therapy Platform
-
COEPTIS’ (COEP) NexGenAI Affiliates Partners with NUBURU (BURU) Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan
-
Coeptis Therapeutics (COEP) NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing
-
Coeptis Therapeutics (COEP) Launches COEP Venture Group
-
Coeptis Therapeutics (COEP) Becomes COEPTIS: Embracing a Future of Technology and Innovation
-
Coeptis Therapeutics (COEP) Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation
-
Coeptis Therapeutics (COEP) Announces First Customer Adoptions of its NexGenAI Marketing Platform
-
Coeptis Therapeutics (COEP) Announces 1:20 Reverse Share Split
-
Coeptis Therapeutics (COEP) Acquires NexGenAI Affiliates Network, Launches Coeptis Technologies
-
Coeptis Therapeutics (COEP) Unveils New Technology Division: Coeptis Technologies
-
Coeptis Therapeutics (COEP) to Acquire NexGenAI Affiliates Network
-
Coeptis Therapeutics (COEP) Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use
-
Coeptis Therapeutics (COEP) Regains Nasdaq Complianc
-
Coeptis Therapeutics (COEP) Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders
-
Ladenburg Thalmann Downgrades Coeptis Therapeutics Holdings, Inc. (COEP) to Neutral

